Autism researchers propose alternative agenda challenging Trump administration priorities

A group of autism researchers is convening in Washington to formally present a research agenda that directly contradicts the direction the Trump administration has been pushing on autism science. The gathering is not a protest. It is a structured scientific counter-proposal, and the fact that it needs to exist at all tells you something about how far the administration's health leadership has drifted from mainstream research consensus on this topic.

At the centre of the tension is HHS Secretary Robert F. Kennedy Jr., who has for years promoted the idea that vaccines cause autism, a claim that has been investigated in studies involving millions of children across multiple countries and consistently found to be false. The largest of those studies, a Danish cohort published in the Annals of Internal Medicine in 2019 covering 650,000 children, found no increased risk of autism in vaccinated versus unvaccinated children. The Trump administration's health apparatus has nonetheless moved to refocus federal autism research funding toward vaccine-related questions and away from the genetic, neurological, and environmental research that the scientific community has been pursuing.

What the alternative research agenda actually proposes

The researchers gathering in Washington are affiliated with institutions including Johns Hopkins, Harvard Medical School, and the University of California San Francisco. Their proposed agenda centres on several areas that the scientific community considers the most productive directions for autism research given what is currently known.

Genetics is the most established area. Large-scale genomic studies have identified hundreds of gene variants associated with autism. The Simons Foundation Autism Research Initiative has catalogued over 900 genes with evidence of autism association in its database as of 2024. Understanding how those variants affect brain development, particularly in the prenatal period, is where the research community believes the most actionable insights will come from over the next decade.

The agenda also covers early intervention research, which has produced the most direct improvements in outcomes for autistic individuals. Applied behaviour analysis and naturalistic developmental behavioural interventions, when delivered early and consistently, have strong evidence bases for improving communication and adaptive skills. Research on which interventions work best for which subgroups of autistic children, and how to expand access to those interventions, is a priority the independent researchers want to protect from budget redirection.

How the administration has shifted federal autism funding

The Interagency Autism Coordinating Committee, which sets federal priorities for autism research funding across NIH, CDC, and other agencies, published its 2024 to 2029 strategic plan before the current administration took office. That plan did not include vaccine-autism research as a priority area. Since January 2025, administration officials have sought to add vaccine safety questions to the IACC's research priorities and have directed NIH programme officers to consider proposals examining environmental toxin and vaccine links to autism that would previously have been unlikely to receive federal funding.

NIH's total autism research budget was approximately $320 million in fiscal year 2024. A redirection of even a fraction of that toward questions the scientific community considers settled would reduce funding available for genetics, neuroscience, and intervention research that autistic individuals and their families consistently cite as the most needed areas in advocacy surveys. The Autistic Self Advocacy Network, in its 2023 research priorities report, placed quality of life, mental health, and access to services as its top three research needs. Vaccine causation was not among them.

The specific theories the administration has promoted

Beyond the vaccine-autism claim, administration-aligned figures have promoted theories involving heavy metal toxicity, including thimerosal, a mercury-containing preservative that was removed from routine childhood vaccines in the United States by 2001, and aluminium adjuvants. Autism diagnosis rates have continued to rise since thimerosal was removed, which the scientific community points to as further evidence against a causal link. The CDC's most recent autism prevalence estimate, published in March 2023, put the rate at 1 in 36 children, up from 1 in 44 in the previous report.

Researchers attribute the rising prevalence primarily to expanded diagnostic criteria and improved screening, which now identify autistic individuals who would previously have been undiagnosed or received different diagnoses. The DSM-5, adopted in 2013, consolidated several previously separate diagnoses into a single autism spectrum disorder category, which directly affected prevalence counts in subsequent surveys.

What the researchers are asking Congress and NIH to do

The group presenting in Washington is asking Congress to pass explicit statutory language protecting IACC's research priorities from executive redirection and to require that any changes to autism research funding priorities go through a peer-reviewed public comment process. They are also asking NIH to maintain the existing peer review standards for grant applications and not to create special review pathways for proposals that would not ordinarily pass scientific merit review.

The group plans to publish its full alternative research agenda in a peer-reviewed journal, with submission targeted for April 2026. A companion open letter has already gathered signatures from over 400 researchers at institutions across 30 countries, according to a statement released before the Washington meeting.